Valeant, J&J, Nestle nab new businesses

Here a deal, there a deal, everywhere a deal today: Three companies have struck sub-billion-dollar agreements, each with a different strategy in mind. Valeant Pharmaceuticals has agreed to buy Sanitas for $443 million, while Johnson & Johnson is in a $260 million deal for a portfolio of Russian over-the-counter meds, and Nestle has snapped up Prometheus Laboratories for a reported $567 million-plus.

Valeant apparently has rebounded from its recent loss of Cephalon to Teva Pharmaceutical Industries. The Canadian company now says it will buy Lithuania's Sanitas for about €314 million in a bid to expand its stable of branded generics in Europe. "With 80 percent of the Sanitas portfolio consisting of non-reimbursed products with limited exposure to government pricing pressures, Valeant will be in a key position to continue our expansion into Central and Eastern Europe," CEO Michael Pearson said.

Meanwhile, J&J has snapped up some OTC medicines now marketed in Russia, from JB Chemicals and Pharmaceuticals. The brands include Russia's leading cough-and-cold line, Rinza, plus the country's No. 2 cough brand, Doktor Mom. The deal came in at about $260 million, Reuters reports.

Finally, Nestle's newly established health science unit has plunked down somewhere between 500 million Swiss francs and 1 billion Swiss francs for Prometheus. The San Diego-based company is predicted to bring in $250 million last year from gastrointestinal and cancer diagnostics and treatments, Bloomberg reports. The Swiss company has said it's intent on establishing a leading business in therapeutic nutrition, and this deal will give it "personalized healthcare solutions based on diagnostics, pharma and nutrition," Nestle Health Science CEO Luis Cantarell said in a statement.

- get the Valeant release
- see the Reuters story
- get more from Reuters
- read the Bloomberg piece

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.